Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|IMC-20D7S||Flanvotumab||Flanvotumab (IMC-20D7S) is a monoclonal antibody that targets TYRP1, which may result in antitumor activity including inhibition of tumor growth (PMID: 27797971).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||IMC-20D7S||Phase Ib/II||Actionable||In a Phase I/Ib trial, treatment with IMC-20D7S in patients with melanoma resulted in stable disease in 37% (10/27) and one complete response (PMID: 27797971).||27797971|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|